Download PDF
Thromb Haemost 2014; 112(05): 853-856
DOI: 10.1160/th14-05-0433
Word Thrombosis Day
Schattauer GmbH

Solving the mystery of excessive warfarin-induced bleeding: A personal historical perspective

Jack Hirsh
1   Professor Emeritus, McMaster University. Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received: 27 May 2014

Accepted after major revision: 27 May 2014

Publication Date:
20 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Butt H, Allen EV, Bollman JL. A preparation from spoiled sweet clover [3,3 -methylene-bis-(4-hydroxycoumarin)] which prolongs coagulation and prothrombin time of the blood: preliminary report of experimental and clinical studies. Proc Staff Meet Mayo Clin 1941; 16: 388-395.
    PubMedGoogle Scholar
  • 2 Link KP. The discovery of dicumarol and its sequels. Circulation 1959; 19: 97-107.
    CrossrefPubMedGoogle Scholar
  • 3 Hull R, Delmore T, Genton E. et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858.
    CrossrefPubMedGoogle Scholar
  • 4 Hull R, Delmore T, Carter C. et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-194.
    CrossrefPubMedGoogle Scholar
  • 5 Poller L, Taberner DA. Dosage and control of oral anticoagulants: an international collaborative survey. Br J Haematol 1982; 51: 479-485.
    CrossrefPubMedGoogle Scholar
  • 6 Hull R, Hirsh J, Jay R. et al. Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein Thrombosis. N Engl J Med 1982; 307: 1676-1681.
    CrossrefPubMedGoogle Scholar
  • 7 Turpie AG, Gunstensen J, Hirsh J. et al. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988; 1: 1242-1245.
    PubMedGoogle Scholar
  • 8 Wright IS, Beck DF, Marple CD. Myocardial infarction and its treatment with anticoagulants; summary of findings in 1031 cases. Lancet 1954; 266: 92-95.
    CrossrefPubMedGoogle Scholar
  • 9 Poller L. A national standard for anticoagulant therapy. The Manchester comparative reagent. Lancet 1967; 1: 491-493.
    PubMedGoogle Scholar
  • 10 Hirsh J, Poller L, Deykin D. et al. Optimal therapeutic range for oral anticoagulants. Chest 1989; 95 (Suppl. 02) 5S-11S.
    PubMedGoogle Scholar
  • 11 WHO Expert Committee on Biological Standardization. 28th Report. Available at: http://whqlibdoc.who.int/trs/WHO_TRS_610.pdf?ua=1. Accessed 9 May, 2014.
    PubMed
  • 12 WHO Expert Committee on Biological Standardization. 33rd Report. Available at: http://whqlibdoc.who.int/trs/WHO_TRS_687.pdf?ua=1. Accessed 9 May, 2014.
    PubMed
  • 13 Poller L. International Normalized Ratios (INR): the first 20 years. J Thromb Haemost 2004; 2: 849-860.
    CrossrefPubMedGoogle Scholar
  • 14 American College of Chest Physicians, National Heart, Lung, and Blood Institute. ACCP-NHLBI National Conference on Antithrombotic Therapy. Chest 1986; 89 (Suppl. 02) 1S-106S.
    CrossrefPubMedGoogle Scholar
  • 15 Stroke Prevention in Atrial Fibrillation Investigators. Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. Stroke 1990; 21: 538-545.
    CrossrefPubMedGoogle Scholar
  • 16 Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527-539.
    CrossrefPubMedGoogle Scholar
  • 17 Poller L, Hirsh J. Special report: a simple system for the derivation of International Normalized Ratios for the reporting of prothrombin time results with North American thromboplastin reagents. Am J Clin Pathol 1989; 92: 124-126.
    CrossrefPubMedGoogle Scholar
  • 18 Hirsh J. Substandard monitoring of warfarin in North America. Time for change. Arch Intern Med 1992; 152: 257-258.
    CrossrefPubMedGoogle Scholar
  • 19 Bussey HI, Force RW, Bianco TM. et al. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy. Arch Intern Med 1992; 152: 278-282.
    CrossrefPubMedGoogle Scholar
  • 20 Hirsh J, Dalen JE, Deykin D. et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992; 102 (Suppl. 04) 312S-326S.
    PubMedGoogle Scholar
  • 21 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
    Article in Thieme ConnectPubMedGoogle Scholar